DengYueMed
Independent Intelligence on Global Oncology & Rare Disease Markets
Policy · Innovation · Market Access · Competitive Strategy
Lead Analysis
Rare Diseases
Oncology
- New Advances in EGFR-Mutated Lung Cancer Treatment: Two Important New Indications Approved in 2026
March 10, 2026 - China’s Innovative Drugs Are Entering the Global Healthcare Supply Chain: New Trends in International Pharmaceutical Distribution
March 09, 2026 - Chinese EGFR and MET Targeted Therapies in NSCLC: Rilertinib, Iruplinal, Rezivertinib and Savolitinib
March 09, 2026
Regulatory
- Southeast Asia's Drug Approval Gap: Why Access to Innovative Therapies Is Lagging
March 11, 2026 - World’s First Semaglutide Nasal Spray Approved by the FDA to Enter Clinical Trials
March 10, 2026 - Birociclib Approved for First-Line Indication: China’s First CDK4/6 Inhibitor Covering the Full Spectrum from First- to Late-Line Treatment
March 06, 2026
Supply Chain
- Southeast Asia's Drug Approval Gap: Why Access to Innovative Therapies Is Lagging
March 11, 2026 - China’s Innovative Drugs Are Entering the Global Healthcare Supply Chain: New Trends in International Pharmaceutical Distribution
March 09, 2026 - New Variables in Global Pharmaceutical Procurement 2026: China’s Innovative Drug Expansion Across Cardiovascular, Oncology and Antiviral Frontiers
March 05, 2026